Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.
We use the technologies from traditional and modern biology combined with computational analysis to develop our organisms at the fastest possible speed. This makes our platform faster and cheaper than chemical synthesis or extraction from the natural source.
We use the technologies from traditional and modern biology combined with computational analysis to develop our organisms at the fastest possible speed. This makes our platform faster and cheaper than chemical synthesis or extraction from the natural source.
Location: Canada, Quebec, Montreal
Employees: 11-50
Total raised: $2.5M
Founded date: 2014
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.10.2020 | - | $2.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 20.04.2022 | How CBD biomanufacturing could make Europe change and win the cannabis game | By now, many have heard about Cannabidiol, better known as CBD, the non-psychoactive cannabinoid derived from the cannabis plant and discovered in 1940. You can find it in products ranging from edible gummy bears to skin oil, for purposes s... |
| 23.10.2020 | Hyasynth completes key commercialization milestone for cannabinoid biosynthesis, receives $2.5 million payment | |
| 07.10.2020 | Hyasynth: Biotech Startup First To To Bring Fermented CBD To Market | 0 2 Mins Read Montreal-based biotechnology company Hyasynth has won the race to become the first to commercialise cannabidiol (CBD) produced and extracted through a yeast fermentation process, without the need for traditional cultivation or... |
| 20.03.2019 | Amyris teams up with LAVVAN to bring fermentation-derived CBD to market in 2020: 'There's a significant cost advantage' | The news follows a string of announcements from firms also developing platforms to biosynthesize cannabinoids via fermentation including Demetrix, Librede; InMed Pharmaceuticals; Hyasynth, which is working with Organingram; Gingk... |
| 13.03.2018 | Agtech Startups Aim to Help the CA Cannabis Market Stay in the Green | Recreational use of cannabis became legal in the state of California on January 1, 2018, and before the end of the month, industry experts were already predicting a coming shortage. The market for legal cannabis in California is estimated t... |
| 13.10.2017 | The Future of Pharmaceutical Cannabis May Be Cultured, Not Cultivated | Hyasynth Bio is a Montreal-based biotech startup that has developed a way to produce the active compounds in cannabis without ever growing a plant. Cannabis’s most plentiful active compounds, the non-psychotropic cannabidiol (CBD), and the ... |
| - | How CBD biomanufacturing could make Europe change and win the cannabis game | By now, many have heard about Cannabidiol, better known as CBD, the non-psychoactive cannabinoid derived from the cannabis plant and discovered in 1940. You can find it in products ranging from edible gummy bears to skin oil, for purposes s... |